Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 14/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 13/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 13/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 12/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5734430 | 1.00 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL7804773 | 0.95 | ADORA3 (0.90) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL6263899 | 0.87 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL5397275 | 0.87 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL6263905 | 0.87 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL4799162 | 0.84 | ADORA2A (0.81) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL5733914 | 0.84 | ADORA2A (0.81) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL12958831 | 0.84 | ADORA2A (0.81) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL13770823 | 0.84 | ADORA2A (0.73) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL5733320 | 0.83 | ADORA2A (0.77) | ADORA3ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1110554-B1 | MEDICINAL COMPOSITIONS FOR TREATING EYE DISEASES | YAMASA CORP (JP) | 2006-03-08 | — | — | EP | claimed |
| US-6387889-B1 | REDUCING OCULAR TENSION | YAMASA CORPORATION (JP) | 2002-05-14 | — | — | US | claimed |
| EP-1110554-A1 | MEDICINAL COMPOSITIONS FOR TREATING EYE DISEASES | YAMASA CORPORATION (JP) | 2001-06-27 | — | — | EP | claimed |
| CN-106377540-B | Bifunctional compounds for the prevention and treatment of neurodegenerative diseases | 中央研究院 | 2019-08-16 | — | — | CN | disclosed |
| US-10342818-B2 | Dual-action compounds targeting adenosine A2A receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases | ACADEMIA SINICA (TW) | 2019-07-09 | — | — | US | disclosed |
| EP-2498774-B1 | DUAL-ACTION COMPOUNDS TARGETING ADENOSINE A2A RECEPTOR AND ADENOSINE TRANSPORTER FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | ACADEMIA SINICA (TW) | 2017-10-11 | — | — | EP | disclosed |
| CN-106377540-A | Bifunctional compounds binding to adenosine A2A receptors and adenosine transporters for the prevention and treatment of neurodegenerative diseases | 中央研究院 | 2017-02-08 | — | — | CN | disclosed |
| CN-102740849-B | Bifunctional compounds binding to adenosine A2A receptors and adenosine transporters for the prevention and treatment of neurodegenerative diseases | ACADEMIA SINICA (CN) | 2016-11-30 | — | — | CN | disclosed |
| US-20150374737-A1 | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases | ACADEMIA SINICA (TW) | 2015-12-31 | — | — | US | disclosed |
| US-20120295863-A1 | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases | ACADEMIA SINICA (TW) | 2012-11-22 | — | — | US | disclosed |
| CN-102740849-A | Binding to adenosine A2ABifunctional compounds of receptor and adenosine transporter for preventing and treating neurodegenerative diseases | ACADEMIA SINICA | 2012-10-17 | — | — | CN | disclosed |
| EP-2498774-A1 | DUAL-ACTION COMPOUNDS TARGETING ADENOSINE A2A RECEPTOR AND ADENOSINE TRANSPORTER FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | Academia Sinica (TW) | 2012-09-19 | — | — | EP | disclosed |
| WO-2012064340-A1 | DUAL-ACTION COMPOUNDS TARGETING ADENOSINE A2A RECEPTOR AND ADENOSINE TRANSPORTER FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | ACADEMIA SINICA (TW) | 2012-05-18 | — | — | WO | disclosed |
| EP-1110554-B1 | MEDICINAL COMPOSITIONS FOR TREATING EYE DISEASES | YAMASA CORP (JP) | 2006-03-08 | — | — | EP | disclosed |
| US-6387889-B1 | REDUCING OCULAR TENSION | YAMASA CORPORATION (JP) | 2002-05-14 | — | — | US | disclosed |
| EP-1110554-A1 | MEDICINAL COMPOSITIONS FOR TREATING EYE DISEASES | YAMASA CORPORATION (JP) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374737-A1 | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases | ADORA2A, ADORA1, ADORA3 | ADORA3 3/4885ADORA2A 1/4885ADORA1 2/4885 |
| US-10342818-B2 | Dual-action compounds targeting adenosine A2A receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases | ADORA2A, ADORA1, ADORA3 | ADORA3 3/4885ADORA2A 1/4885ADORA1 2/4885 |
| US-20120295863-A1 | Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases | ADORA2A, ADORA1, ADORA3 | ADORA3 3/4885ADORA2A 1/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.